If you want to understand a biotech franchise, don't read the marketing — read its patents in order. For Genentech's anti-VEGF eye program, that record tells a clear, layered story, and it starts with one target: VEGF, the protein behind the leaky vessels that cause vision loss.
Layer one is the molecule. An antibody is a large protein engineered to grab one target and hold on. But a first-generation antibody is rarely the final product — it gets refined.
Layer two is optimization, and this is where Genentech's US10899828B2 sits: optimized variants of anti-VEGF antibodies. In plain terms, the company re-engineered the protein to behave better — bind tighter, last longer, or tolerate the harsh environment of the eye — and patented those specific variants. The companion publication US20210115124A1 stakes out the same optimized-variant ground.
Layer three is the part readers overlook: the formulation. Publication US20210363231A1 covers optimized antibody compositions for treating ocular disorders — the actual injectable preparation. A molecule you can't formulate into a safe, stable eye injection isn't a product.
Why does this layering matter to a reader trying to value the franchise? Because protection isn't a single date on a single patent. The molecule, the variants, and the formulation can expire at different times, and a competitor has to clear all the live ones. That is what turns a drug into a moat.
The short version is that Genentech's anti-VEGF program reads, in the patent record, like a building rather than a brick. Each floor — molecule, variant, formulation — is separately deeded. Understanding that structure is the difference between thinking a franchise is about to fall and seeing why it tends to hold.